


PGD2-IN-1

Cat. No.:	HY-101430		
CAS No.:	885066-67-1		
Molecular Formula:	C ₂₃ H ₂₃ Cl ₂ N ₃ O ₃		
Molecular Weight:	460.35		
Target:	Prostaglandin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (54.31 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions		10 mg	
	1 mM	2.1723 mL	10.8613 mL	21.7226 mL
	5 mM	0.4345 mL	2.1723 mL	4.3445 mL
	10 mM	0.2172 mL	1.0861 mL	2.1723 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	PGD2-IN-1 is an antagonist of DP extracted from patent WO 2006044732 A2, example 15 (d); has an IC ₅₀ of 0.3 nM.
IC ₅₀ & Target	IC50: 0.3 nM ^[1]
In Vitro	Prostaglandin D2 (PGD2) is a major inflammatory mediator implicated in asthma and allergic rhinitis. It is largely produced as the major cyclooxygenase metabolite upon allergen-provoked degranulation from mast cells. Blockage of PGD2 using DP antagonists has been shown to be effective at alleviating the symptoms of allergic rhinitis in multiple species and more specifically has been shown to inhibit the antigen-induced nasal congestion ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lim, Sungtaek, et al. 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS. WO2006044732A2.

[2]. Mu L, et al. Understanding DP receptor antagonism using a CoMSIA approach. Bioorg Med Chem Lett. 2011 Jan 1;21(1):66-75.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA